Impact BioMedical Inc. (IBO)
NYSEAMERICAN: IBO · Real-Time Price · USD
0.660
0.00 (0.00%)
At close: Apr 28, 2026, 4:00 PM EDT
0.636
-0.024 (-3.67%)
Pre-market: Apr 29, 2026, 4:09 AM EDT
Impact BioMedical Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 0.03 | - | - | 0.05 | - | |
| Cost of Revenue | 0.42 | - | - | - | - | |
| Gross Profit | -0.39 | - | - | 0.05 | - | |
| Selling, General & Admin | 1.98 | 1.83 | 1.1 | 1.12 | 0.99 | |
| Research & Development | 0.34 | 0.28 | 1.69 | 1.23 | 1.08 | |
| Other Operating Expenses | 0.42 | 0.17 | 0.12 | - | - | |
| Operating Expenses | 3.88 | 3.4 | 4.03 | 3.45 | 3.19 | |
| Operating Income | -4.27 | -3.4 | -4.03 | -3.4 | -3.19 | |
| Interest Expense | -0.79 | -1.07 | -0.44 | -0.46 | -0.3 | |
| Interest & Investment Income | 0.01 | 0.01 | 0.01 | 0.02 | 0.17 | |
| Other Non Operating Income (Expenses) | -9.39 | 5.07 | 0.05 | 0.07 | 0.08 | |
| EBT Excluding Unusual Items | -14.44 | 0.62 | -4.41 | -3.78 | -3.24 | |
| Impairment of Goodwill | - | -25.09 | - | - | - | |
| Gain (Loss) on Sale of Investments | - | - | - | -4.1 | - | |
| Gain (Loss) on Sale of Assets | -0.01 | - | - | - | - | |
| Asset Writedown | - | -0.26 | - | - | - | |
| Pretax Income | -14.45 | -24.74 | -4.41 | -7.88 | -3.24 | |
| Income Tax Expense | -2.58 | 0.03 | - | -0.62 | -1.4 | |
| Earnings From Continuing Operations | -11.87 | -24.77 | -4.41 | -7.26 | -1.85 | |
| Minority Interest in Earnings | 0.03 | 0.06 | 0.07 | 0.2 | 0.55 | |
| Net Income | -11.84 | -24.71 | -4.34 | -7.05 | -1.3 | |
| Net Income to Common | -11.84 | -24.71 | -4.34 | -7.05 | -1.3 | |
| Shares Outstanding (Basic) | 32 | 11 | 60 | 70 | 70 | |
| Shares Outstanding (Diluted) | 32 | 11 | 60 | 70 | 70 | |
| Shares Change (YoY) | 193.30% | -82.14% | -14.54% | - | - | |
| EPS (Basic) | -0.38 | -2.30 | -0.07 | -0.10 | -0.02 | |
| EPS (Diluted) | -0.38 | -2.30 | -0.07 | -0.10 | -0.02 | |
| Free Cash Flow | -1.89 | -2.85 | -2.87 | -2.52 | -2.03 | |
| Free Cash Flow Per Share | -0.06 | -0.27 | -0.05 | -0.04 | -0.03 | |
| Gross Margin | - | - | - | 100.00% | - | |
| Operating Margin | -13343.75% | - | - | -6808.00% | - | |
| Profit Margin | -36993.75% | - | - | -14102.00% | - | |
| Free Cash Flow Margin | -5906.25% | - | - | -5036.00% | - | |
| EBITDA | -3.13 | -3.39 | -4.02 | -2.29 | -2.07 | |
| D&A For EBITDA | 1.15 | 0.01 | 0.01 | 1.11 | 1.11 | |
| EBIT | -4.27 | -3.4 | -4.03 | -3.4 | -3.19 | |
| Revenue as Reported | 0.03 | - | - | - | - | |
Source: S&P Capital IQ. Standard template.
Financial Sources.